(Q53120165)

11 May 2018

title

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. (English)

1 reference

11 May 2018

0 references

1 reference

1

Irit Avivi

1 reference

11 May 2018

author name string

Ariel Zilberlicht

2

1 reference

11 May 2018

Eldad J Dann

3

1 reference

11 May 2018

Ronit Leiba

4

1 reference

11 May 2018

Tal Faibish

5

1 reference

11 May 2018

Jacob M Rowe

6

1 reference

11 May 2018

Rachel Bar-Shalom

7

1 reference

11 May 2018

publication date

19 March 2013

1 reference

11 May 2018

American Journal of Hematology

published in

1 reference

11 May 2018

volume

88

1 reference

11 May 2018

issue

5

1 reference

11 May 2018

page(s)

400-405

1 reference

11 May 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

cites work

1 reference

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

21 January 2018

1 reference

A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma

21 January 2018

1 reference

The case against heavy PETing

21 January 2018

1 reference

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

21 January 2018

1 reference

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

21 January 2018

1 reference

Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation

21 January 2018

1 reference

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

21 January 2018

1 reference

Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma

21 January 2018

1 reference

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

21 January 2018

1 reference

Accuracy of Whole‐Body 18F‐FDP‐PET for Restaging Malignant Lymphoma

21 January 2018

1 reference

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

21 January 2018

1 reference

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

21 January 2018

1 reference

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Routine follow-up scanning of patients with lymphoma: who, when, how, and why?

21 January 2018

1 reference

Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23423

1 reference

11 May 2018

1 reference

11 May 2018